Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
3.250
-0.140 (-4.13%)
At close: Dec 5, 2025, 4:00 PM EST
3.310
+0.060 (1.85%)
After-hours: Dec 5, 2025, 5:14 PM EST
Company Description
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders.
The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Camp4 Therapeutics Corporation
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Joshua Mandel-Brehm |
Contact Details
Address: One Kendall Square, 3rd Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 617 651 8867 |
| Website | camp4tx.com |
Stock Details
| Ticker Symbol | CAMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001736730 |
| CUSIP Number | 13463J101 |
| ISIN Number | US13463J1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua Mandel-Brehm | Chief Executive Officer, President and Director |
| Dr. Richard A. Young Ph.D. | Founder and Independent Director |
| Kelly Gold | Chief Financial Officer |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
| Dr. Leonard I. Zon M.D. | Founder and Chairman of Scientific Advisory Board |
| Caleb Moore | Chief Business Operations Officer |
| Dr. Daniel Tardiff Ph.D. | Chief Scientific Officer |
| Michelle Gates | Senior Vice President and Chief People Officer |
| Dr. David Bumcrot Ph.D. | Senior Vice President of Research |
| Alla Sigova Ph.D. | Senior Vice President of Platform |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 1, 2025 | 424B5 | Filing |
| Nov 25, 2025 | 424B3 | Prospectus |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 7, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 7, 2025 | SCHEDULE 13G | Filing |